Source comparison
MK-677 Muscle Growth Results Timeline Comparison
First measurable lean mass increase Week 8–12 Week 3–4 Month 3–6 MK-677 delays reflect IGF-1 upregulation lag vs direct androgen receptor binding Peak hypertrophic velocity Months 4–6 Weeks 6–10 Months 6–12 Testosterone produces faster initial gains; MK-677 sh
This comparison does not assign a generated winner or score.
- First measurable lean mass increase
- Week 8–12
- Week 3–4
- Month 3–6
- MK-677 delays reflect IGF-1 upregulation lag vs direct androgen receptor binding
- Peak hypertrophic velocity
- Months 4–6
- Weeks 6–10
- Months 6–12
- Testosterone produces faster initial gains; MK-677 shows sustained but slower accrual
- Total lean mass gain (12 months)
- 2.7kg mean (JCEM study)
- 6–8kg typical (observational data)
- 2–4kg (trained individuals)
- MK-677 gains modest but occur without androgenic side effects or HPTA suppression
- Strength increase at 6 months
- 18–22% above baseline
- 30–40% above baseline
- 12–18% above baseline
- Strength gains from MK-677 primarily Type II fiber hypertrophy, not neuromuscular adaptation
- Myonuclear addition (satellite cell fusion)
- Significant after month 3
- Immediate (weeks 2–4)
- Gradual across 6+ months
- Myonuclear permanence from MK-677 may allow easier muscle regain post-cessation
- Professional Assessment
- Best for sustained, side-effect-minimal hypertrophy in research settings; requires patience and structured training to realize potential
- Fastest absolute gains but with significant androgenic load and suppression risk
- Slowest timeline but establishes natural baseline; ideal for comparing compound efficacy